Selected for a Distinguished Oral Plenary Presentation SOLANA BEACH, Calif. , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)
SOLANA BEACH, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it has been granted a
40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation
“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” SOLANA BEACH, Calif. , and CHICAGO , July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation SOLANA BEACH, Calif. , June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for
Net product sales increased by 94% from Q1 2022 New cumulative prescribers up by 17% from Q4 2022 Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily
Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramide SOLANA BEACH, Calif.
Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif. , May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for
Broad Formulation Patent Expands Protection for Gimoti SOLANA BEACH, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)
